SUDAFED 24 HOUR Drug Patent Profile
✉ Email this page to a colleague
When do Sudafed 24 Hour patents expire, and what generic alternatives are available?
Sudafed 24 Hour is a drug marketed by J And J Consumer Inc and is included in one NDA.
The generic ingredient in SUDAFED 24 HOUR is pseudoephedrine hydrochloride. There are forty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the pseudoephedrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sudafed 24 Hour
A generic version of SUDAFED 24 HOUR was approved as pseudoephedrine hydrochloride by L PERRIGO CO on February 26th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUDAFED 24 HOUR?
- What are the global sales for SUDAFED 24 HOUR?
- What is Average Wholesale Price for SUDAFED 24 HOUR?
Summary for SUDAFED 24 HOUR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Clinical Trials: | 11 |
Patent Applications: | 1,536 |
DailyMed Link: | SUDAFED 24 HOUR at DailyMed |
Recent Clinical Trials for SUDAFED 24 HOUR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
John Muir Health | N/A |
National Center for Advancing Translational Science (NCATS) | Early Phase 1 |
Vanderbilt University | Early Phase 1 |
Pharmacology for SUDAFED 24 HOUR
Drug Class | alpha-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists |
US Patents and Regulatory Information for SUDAFED 24 HOUR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J And J Consumer Inc | SUDAFED 24 HOUR | pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020021-002 | Dec 15, 1992 | OTC | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUDAFED 24 HOUR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
J And J Consumer Inc | SUDAFED 24 HOUR | pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020021-002 | Dec 15, 1992 | 4,576,604 | ⤷ Subscribe |
J And J Consumer Inc | SUDAFED 24 HOUR | pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020021-002 | Dec 15, 1992 | 4,801,461 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUDAFED 24 HOUR
See the table below for patents covering SUDAFED 24 HOUR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 162470 | ⤷ Subscribe | |
Denmark | 88884 | ⤷ Subscribe | |
Ireland | 56606 | OSMOTIC SYSTEM WITH INSTANT DRUG AVAILABILITY | ⤷ Subscribe |
Germany | 3407873 | ⤷ Subscribe | |
Japan | S63258409 | PSEUDOEPHEDRINE ADMINISTRATIVE MEDICINE | ⤷ Subscribe |
Israel | 71112 | OSMOTIC SYSTEM WITH INSTANT DRUG AVAILABILITY | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SUDAFED 24 HOUR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1110543 | 08C0004 | France | ⤷ Subscribe | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Subscribe | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |